FIREBRICK PHARMA LIMITED
ASX:FREPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 86.7% of what they think they own, once every option and right converts.
Share count grew 47% in 24 months; runway 2–4 quarters; 6 cash raises in 24 months
FIREBRICK PHARMA LIMITED's ordinary share count grew 46.6% between October 2024 and October 2026, its latest share-count filing, to 308M shares. The company raised capital six times in that period for total disclosed proceeds of A$5.0M, most recently a A$732K placement in October 2026. Options and rights on issue could convert into 47M new shares, equal to 15.3% of the current share count, none of which are in the money at the current share price; the nearest expiry falls in September 2027. The company has 2 to 4 quarters of funding at the recent spend rate. No proposed securities issues (Appendix 3B) are currently pending.
Quick answers · 5
When did FRE last raise capital?
The last capital raise in Firebrick Pharma's filings is Placement of $732k announced 12 Oct 2026, one of 6 cash raises in 24 months.
How much placement capacity does FRE have left?
About 5% of the 15% placement capacity left, about 95% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does FRE have?
In its quarterly cash report for the quarter ended 30 Sept 2026, Firebrick Pharma reported $875k of cash and estimated 2.2 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do FRE's options expire?
Unexercised options and rights equal 15.3% of Firebrick Pharma's shares on issue; the nearest expiry is Sept 2027.
How much has FRE's share count grown?
Firebrick Pharma has 308.1M shares on issue as at 28 Oct 2026, up 46.6% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 19 Oct 2026 | 2A · quoted issue | FRE : ORDINARY FULLY PAID | 308.1M | Appendix 2A |
| 11 Aug 2026 | 2A · quoted issue | FRE : ORDINARY FULLY PAID | 287.2M | Appendix 2A |
| 27 July 2026 | 3G · unquoted | FRE : ORDINARY FULLY PAID | 285.2M | Appendix 3G |
| 2 June 2026 | 2A · quoted issue | FRE : ORDINARY FULLY PAID | 285.2M | Appendix 2A |
| 1 June 2026 | 3H · cancellation | FRE : ORDINARY FULLY PAID | 285.0M | Appendix 3H |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
6 cash raises in the last 24 months · 2 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
An exercise price is on record for only 25.8% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.028 today. No more priced supply until 5× today’s price, which takes it to 9.2M (3.0% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 35.0M (74.2% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| FREAD | Options | Price-triggered | $0.090 | 8 Sept 2027 | 1.5M | Filing |
| FREO | Options | Price-triggered, no exercise price stated | — | 4 July 2028 | 34.8M | Filing |
| FREAG | Options | Price-triggered | $0.15 | 1 Aug 2029 | 1.0M | Filing |
| FREAH | Options | Price-triggered | $0.12 | 1 Oct 2029 | 7.7M | Filing |
| FREAI | Options | Price-triggered | $0.15 | 10 Feb 2030 | 1.0M | Filing |
| FREAJ | Options | Price-triggered | $0.15 | 17 Apr 2031 | 1.0M | Filing |
| FREAB | Options | Price-triggered, no exercise price stated | — | — | 200k | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 20 May 2026 | Peter Laurence Molloy | Buy on-market | 245k | — | — | $10k | 3Y notice |
| 20 May 2026 | Stephen Francis Goodall | Buy on-market | 110k | — | — | $5k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.